Nakajima M, Tanaka K, Yoneshima Y, Yamashita S, Shibahara D, Iwama E, Okamoto I

YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells.

Biochem Biophys Res Commun 681: 120-126, 2023Pubmed

Okamura K, Inoue H, Tanaka K, Ikematsu Y, Furukawa R, Ota K, Yoneshima Y, Iwama E, Okamoto I

Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma.

Cancer Sci 114(3): 1095-1107, 2023Pubmed

Shibahara D, Akanuma N, Kobayashi SI, Heo E, Ando M, Fujii M, Jiang F, Prin PN, Pan G, Wong KK, Costa DB, Bararia D, Tenen DG, Watanabe H, Kobayashi SS

TIP60 is required for tumorigenesis in non-small cell lung cancer.

Cancer Sci 114(6): 2400-2413, 2023Pubmed

Nakanishi T, Yoneshima Y, Okamura K, Yanagihara T, Hashisako M, Iwasaki T, Haratake N, Mizusaki S, Ota K, Iwama E, Takenaka T, Tanaka K, Yoshizumi T, Oda Y, Okamoto I

MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma.

Cancer Sci 114(10): 4101-4113, 2023Pubmed

Hirayama A, Tanaka K, Tsutsumi H, Nakanishi T, Yamashita S, Mizusaki S, Ishii Y, Ota K, Yoneshima Y, Iwama E, Okamoto I

Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1β.

Front Immunol 14: 1192861, 2023Pubmed

Tanaka K, Nakanishi Y, Okamoto I

Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers.

Lung Cancer 175: 101-111, 2023Pubmed

Tsutsumi H, Inoue H, Shiraishi Y, Hirayama A, Nakanishi T, Ando H, Nakajima M, Shinozaki S, Ogata H, Okamura K, Kimura S, Ogawa T, Ota K, Yoneshima Y, Tanaka K, Hamada N, Okamoto I, Iwama E

Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors.

Lung Cancer 181: 107264, 2023Pubmed

Iwama E, Yamamoto H, Okubo F, Ijichi K, Ibusuki R, Shiaraishi Y, Yoneshima Y, Tanaka K, Oda Y, Okamoto I

Evaluation of appropriate conditions for Oncomine DxTT testing of FFPE specimens for driver gene alterations in non-small cell lung cancer.

Thorac Cancer 14(23): 2288-2296, 2023Pubmed

Nakashima T, Shiraishi Y, Shiota A, Yoneshima Y, Iwama E, Tanaka K, Okamoto I

Afatinib-induced bronchiolitis obliterans.

Curr Probl Cancer 10: 100231, 2023Article

Isa K, Tanaka K, Shiraishi Y, Yoneshima Y, Iwama E, Okamoto I

Osimertinib failure followed by successful treatment of afatinib in a patient with compound uncommon, G719S and V834L mutations.

Curr Probl Cancer 10: 100236, 2023Article

Tsuneoka K, Tanaka K, Shimauchi A, Inoue S, Yoneshima Y, Ikegame S, Harada E, Okamoto I

A Case of Obstructing Bronchial Aspergillosis in a Patient Receiving Cytotoxic Chemotherapy and Inhaled Corticoid Therapy.

RESPEND 1(2): 105-108, 2023Article

Shiraishi Y, Sekino Y, Horinouchi H, Ohe Y, Okamoto I

High incidence of cytokine release syndrome in patients with advanced NSCLC treated with nivolumab plus ipilimumab.

Ann Oncol 34(11): 1064-1065, 2023Pubmed